Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE
    • Publication Information:
      Publication: Alexandria Va : American Diabetes Association
      Original Publication: New York, American Diabetes Assn.
    • Subject Terms:
      Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Cardiovascular Diseases*; Humans ; Canagliflozin/therapeutic use ; Albuminuria/drug therapy ; Kidney
    • Abstract:
      Objective: The study was undertaken because it was unknown whether the duration of type 2 diabetes modifies the effects of sodium-glucose cotransporter 2 inhibitor canagliflozin on cardiovascular (CV) and kidney outcomes.
      Research Design and Methods: This post hoc analysis of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program (N = 10,142) and Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) trial (N = 4,401) evaluated hazard ratios and 95% CIs using Cox proportional hazards for the effects of canagliflozin on CV and kidney outcomes, including progression and regression of albuminuria over 5-year intervals of disease duration.
      Results: Canagliflozin had ranges of benefit across intervals of diabetes duration, with no heterogeneity for major adverse CV events, CV death or heart failure hospitalization, and kidney failure requiring therapy or doubling serum creatinine. Furthermore, canagliflozin reduced albuminuria progression and increased albuminuria regression with no interaction across all diabetes duration subgroups.
      Conclusions: Our findings suggest that earlier treatment with canagliflozin confers consistent cardiorenal benefits to individuals with type 2 diabetes.
      (© 2024 by the American Diabetes Association.)
    • References:
      Diabetes Obes Metab. 2017 Mar;19(3):387-393. (PMID: 28120497)
      Diabetes Obes Metab. 2021 Feb;23(2):382-390. (PMID: 33043620)
      Eur Heart J. 2020 Jan 7;41(2):255-323. (PMID: 31497854)
      Diabetes Obes Metab. 2017 Jul;19(7):926-935. (PMID: 28244644)
      N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
      N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: 30990260)
      Drug Saf. 1999 Feb;20(2):109-17. (PMID: 10082069)
      Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. (PMID: 29937267)
      Am J Kidney Dis. 2021 Apr;77(4 Suppl 1):A7-A8. (PMID: 33752804)
      Am J Nephrol. 2017 Dec 13;46(6):462-472. (PMID: 29253846)
      Kidney Int. 2021 Mar;99(3S):S1-S87. (PMID: 33637192)
    • Grant Information:
      Janssen Canada Inc.
    • Accession Number:
      0SAC974Z85 (Canagliflozin)
      0 (Sodium-Glucose Transporter 2 Inhibitors)
    • Publication Date:
      Date Created: 20240122 Date Completed: 20240226 Latest Revision: 20240306
    • Publication Date:
      20240306
    • Accession Number:
      PMC10909678
    • Accession Number:
      10.2337/dc23-1450
    • Accession Number:
      38252809